SEC Form 4
Pulse Biosciences, Inc (PLSE) insider trading
In the 12 months to Nov 17, 2026, one PLSE insider reported open-market sales of $2.9M across 3 filings; 2 insiders bought $13.2M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $2.9M
- 3 filings · 1 insider
- Open-market purchases
- $13.2M
- 3 filings
- Pre-arranged sales (10b5-1)
- 3 of 3
- All $2.9M sold was pre-arranged
Who traded PLSE, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
PLSE daily close from Nov 17, 2025 to Nov 16, 2026, between $12.66 and $58.17, last $46.36. 3 sale and 3 purchase filings by 3 insiders, marked at their filing dates. Robert W. Duggan, Director: bought $13.0M across 1 filing, first filed May 15, 2026, last May 15, 2026. Kevin Patrick Danahy, Chief Commercial Officer: sold $2.9M across 3 filings, first filed Feb 11, 2026, last Feb 23, 2026. Liane Rae Teplitsky, Chief Operating Officer: bought $199.9K across 2 filings, first filed Aug 28, 2026, last Sep 2, 2026.
Largest mark · tap a row for others
Robert W. Duggan · Director
Purchase $12,999,988
660,233 shares at $19.69 avg
Filed May 15, 2026 · traded May 11
Close on filing date $24.55
Robert W. Duggan · Director
Director
$13.0M boughtKevin Patrick Danahy · Chief Commercial Officer
Chief Commercial Officer
$2.9M soldLiane Rae Teplitsky · Chief Operating Officer
Chief Operating Officer
$199.9K boughtOpen-market trades
6 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Robert W. Duggan | Director | — | $13.0M | 1 | — | |
| Kevin Patrick Danahy | Chief Commercial Officer | $2.9M | — | 3 | 100% of sales | |
| Liane Rae Teplitsky | Chief Operating Officer | — | $199.9K | 2 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Liane Rae Teplitsky Chief Operating Officer | Purchase | 2,025 | $49.37 | $100.0K | 4,095 | |
traded | Liane Rae Teplitsky Chief Operating Officer | Purchase | 2,070 | $48.29 | $100.0K | 2,070 | |
traded | Robert W. Duggan Director | Purchase | 660,233 | $19.69 | $13.0M | 48,370,047 | |
traded | Kevin Patrick Danahy Chief Commercial Officer | SalePre-arranged (10b5-1) | 5,000 | $23.64 | $118.2K | 43,298 | |
traded | Kevin Patrick Danahy Chief Commercial Officer | SalePre-arranged (10b5-1) | 60,000 | $23.51 | $1.4M | 43,298 | |
traded | Kevin Patrick Danahy Chief Commercial Officer | SalePre-arranged (10b5-1) | 60,000 | $23.39 | $1.4M | 43,298 |
GET /stocks/filings/vX/form-4?tickers=PLSE&filing_date.gte=2025-11-17&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"PLSE"
],
"issuer_cik": "0001625101",
"owner_cik": "0002132552",
"accession_number": "0001437749-26-029545",
"form_type": "4",
"filing_date": "2026-09-02",
"period_of_report": "2026-08-31",
"issuer_name": "PULSE BIOSCIENCES, INC.",
"issuer_trading_symbol": "PLSE",
"owner_name": "Teplitsky Liane Rae",
"is_officer": true,
"officer_title": "Chief Operating Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-01",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 1001,
"transaction_price_per_share": 49.95,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 4095,
"transaction_value": 49999.950000000004,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws."
},
{
"id": "F2",
"description": "The purchase of fractional shares has been rounded down to the nearest whole number."
},
{
"id": "F4",
"description": "Open market purchase transactions made on the same day at the same price through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred at the reported price."
}
]
},
{
"tickers": [
"PLSE"
],
"issuer_cik": "0001625101",
"owner_cik": "0002132552",
"accession_number": "0001437749-26-029545",
"form_type": "4",
"filing_date": "2026-09-02",
"period_of_report": "2026-08-31",
"issuer_name": "PULSE BIOSCIENCES, INC.",
"issuer_trading_symbol": "PLSE",
"owner_name": "Teplitsky Liane Rae",
"is_officer": true,
"officer_title": "Chief Operating Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-31",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 1024,
"transaction_price_per_share": 48.8,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 3094,
"transaction_value": 49971.2,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws."
},
{
"id": "F2",
"description": "The purchase of fractional shares has been rounded down to the nearest whole number."
},
{
"id": "F3",
"description": "Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $48.76 to $48.80 per share."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 8 records
- Option exercises7 records
- Employee stock purchase plan1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Pulse Biosciences, Inc's CEO sold stock?
No. Paul A. Laviolette (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is PLSE’s insider data?
These are PLSE Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track PLSE insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for PLSE every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.